Anavex Life Sciences Corp.
Anavex Life Sciences Corp. (AVXL) PE Ratio — Current & Historical Data
Trailing twelve months (TTM) P/E, forward P/E, PEG, and annual PE history — from market prices and filings.
avxl · pe ratio · data through Sep 30, 2025
Core PE Ratio Metrics
Trailing 12 months · TTMThe price-to-earnings (P/E) ratio for Anavex Life Sciences Corp. (AVXL) measures how much investors pay for each dollar of the company's trailing earnings. AVXL's current PE ratio of N/A is calculated by dividing its stock price of $2.57 by its TTM earnings per share of -$0.45.
Source: FMP · /ratios-ttm · /analyst-estimates · 2025-09-30
PE Ratio History
2006 – 2025 · Annual▸ FMP /ratios?period=annual&limit=20 · priceToEarningsRatio + netIncomePerShare (Annual)
PE Ratio vs Peers
Biotechnology · 6 peers · Annual PE| Company | Market Cap | PE (Annual) | vs Avg | EPS (TTM) |
|---|---|---|---|---|
Anavex Life Sciences Corp.You AVXL | $239M | N/A | — | -$0.45 |
 Absci Corporation ABSI | $1.0B | N/A | — | -$0.84 |
 Arvinas, Inc. ARVN | $485M | N/A | — | -$1.24 |
 Astria Therapeutics, Inc. ATXS | $718M | N/A | — | -$1.68 |
 CytomX Therapeutics, Inc. CTMX | $474M | N/A | — | -$0.13 |
 Erasca, Inc. ERAS | $3.9B | N/A | — | -$0.44 |
 MBX Biosciences, Inc. Common Stock MBX | $989M | N/A | — | -$2.38 |
* N/A — Company is not profitable (TTM) · excluded from industry average · ▸ FMP /stock-peers + /ratios?limit=1 · priceToEarningsRatio
Annual PE Ratio History
| Fiscal Year End | PE Ratio | EPS (TTM) | YoY Change | PE vs Max |
|---|---|---|---|---|
2025-09-30Latest FY2025 | — | $-0.54 | — | |
2024-09-30 FY2024 | — | $-0.52 | — | |
2023-09-30 FY2023 | — | $-0.60 | — | |
2022-09-30 FY2022 | — | $-0.62 | — | |
2021-09-30 FY2021 | — | $-0.54 | — | |
2020-09-30 FY2020 | — | $-0.45 | — | |
2019-09-30 FY2019 | — | $-0.54 | — | |
2018-09-30 FY2018 | — | $-0.39 | — | |
2017-09-30 FY2017 | — | $-0.33 | — | |
2016-09-30 FY2016 | — | $-0.42 | — |
▸ FMP /ratios?period=annual&limit=20 · priceToEarningsRatio + netIncomePerShare · Zero extra API
About PE Ratio & Methodology
The price-to-earnings (P/E) ratio for Anavex Life Sciences Corp. (AVXL) measures how much investors pay for each dollar of the company's trailing earnings. AVXL's current PE ratio of N/A is calculated by dividing its stock price of $2.57 by its TTM earnings per share of -$0.45.
Frequently asked questions
AVXL pe ratio · 6 questionsAVXL's current PE ratio is N/A as of 2026-06-08, based on a stock price of $2.57 and TTM EPS of -$0.45. Data sourced from Financial Modeling Prep via AVXL's SEC 10-K and 10-Q filings.
▸ Source: FMP · /ratios-ttm · /ratios annual · /analyst-estimates · /stock-peers · Anavex Life Sciences Corp. SEC 10-K & 10-Q filings · US GAAP · Updated: 2026-06-08